Prudential Financial Inc. Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Prudential Financial Inc. grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.5% in the second quarter, according to its most recent filing with the SEC. The fund owned 61,317 shares of the biopharmaceutical company’s stock after acquiring an additional 3,768 shares during the quarter. Prudential Financial Inc. owned about 0.06% of Regeneron Pharmaceuticals worth $32,191,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of REGN. Cove Private Wealth LLC lifted its position in Regeneron Pharmaceuticals by 4.5% during the first quarter. Cove Private Wealth LLC now owns 460 shares of the biopharmaceutical company’s stock valued at $292,000 after purchasing an additional 20 shares during the last quarter. Marino Stram & Associates LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 5.3% in the 2nd quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock valued at $208,000 after acquiring an additional 20 shares during the last quarter. Activest Wealth Management grew its position in Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 21 shares in the last quarter. CX Institutional increased its stake in Regeneron Pharmaceuticals by 7.9% during the second quarter. CX Institutional now owns 302 shares of the biopharmaceutical company’s stock worth $159,000 after acquiring an additional 22 shares during the last quarter. Finally, Redwood Wealth Management Group LLC raised its position in Regeneron Pharmaceuticals by 4.8% during the second quarter. Redwood Wealth Management Group LLC now owns 506 shares of the biopharmaceutical company’s stock valued at $266,000 after purchasing an additional 23 shares during the period. Institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Bank of America lifted their target price on Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the stock an “underperform” rating in a report on Wednesday, October 29th. Guggenheim lifted their price objective on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 14th. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, November 18th. Finally, Royal Bank Of Canada upped their price target on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a report on Wednesday, October 29th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $757.91.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the sale, the vice president directly owned 4,233 shares in the company, valued at $2,757,503.19. The trade was a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Christine A. Poon sold 6,500 shares of the stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the transaction, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.7%

NASDAQ:REGN opened at $761.45 on Tuesday. The company has a market cap of $80.03 billion, a price-to-earnings ratio of 18.23, a price-to-earnings-growth ratio of 2.03 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $800.99. The company has a current ratio of 4.06, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The stock has a fifty day simple moving average of $619.07 and a 200-day simple moving average of $577.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping the consensus estimate of $9.73 by $2.10. The company had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm’s revenue was up .9% compared to the same quarter last year. During the same quarter last year, the firm posted $12.46 EPS. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Thursday, November 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.5%. The ex-dividend date is Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.43%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.